期刊文献+
共找到98篇文章
< 1 2 5 >
每页显示 20 50 100
Resection of a locally advanced hilar tumor and the hepatic artery after stepwise hepatic arterial embolization: A case report 被引量:1
1
作者 Takuya Miura Kenichi Hakamada +11 位作者 Takashi Ohata Shunji Narumi Yoshikazu Toyoki Masaki Nara Keinosuke Ishido Motonari Ohashi Harue Akasaka Hiroyuki Jin Norihito Kubo Shuichi Ono Hiroshi Kijima Mutsuo Sasaki 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第22期3587-3590,共4页
We herein report a case of a hilar tumor with extensive invasion to the proper hepatic artery, which was successfully treated with a radical resection in a 57-year-old female patient after a stepwise hepatic arterial ... We herein report a case of a hilar tumor with extensive invasion to the proper hepatic artery, which was successfully treated with a radical resection in a 57-year-old female patient after a stepwise hepatic arterial embolization. She underwent right colectomy and partial hepatectomy for advanced colon cancer two years ago and radiofrequency ablation therapy for a liver metastasis one year ago, respectively. A recurrent tumor was noted around the proper hepatic artery with invasion to the left hepatic duct and right hepatic artery 7 mo previously. We planned a radical resection for the patient 5 mo after the absence of tumor progression was confirmed while he was undergoing chemotherapy. To avoid surgery-related liver failure, we tried to promote the formation of collateral hepatic arteries after stepwise arterial embolizationof the posterior and anterior hepatic arteries two weeks apart. Finally, the proper hepatic artery was occluded after formation of collateral flow from the inferior phrenic and superior mesenteric arteries was confirmed. One month later, a left hepatectomy with hepatic arterial resection was successfully performed without any major complications. 展开更多
关键词 肝动脉栓塞 门肿瘤 动脉切除术 间接动脉
下载PDF
ERCP与经口胰胆管镜技术置入胆管支架在高位胆管癌中的疗效对比分析
2
作者 李鹏 宋展 +2 位作者 刘驰 戴兵 李琼 《现代消化及介入诊疗》 2024年第3期270-273,280,共5页
目的探讨经ERCP与经口胰胆管镜技术行胆管支架置入在高位胆管癌中的疗效。方法回顾性分析2021年1月至2023年9月在南阳市中心医院行胆管支架置入的136例高位胆管癌患者临床资料。根据胆管支架置入方式分为ERCP组(86例)和经口胰胆管镜组(5... 目的探讨经ERCP与经口胰胆管镜技术行胆管支架置入在高位胆管癌中的疗效。方法回顾性分析2021年1月至2023年9月在南阳市中心医院行胆管支架置入的136例高位胆管癌患者临床资料。根据胆管支架置入方式分为ERCP组(86例)和经口胰胆管镜组(50例)。比较两组患者年龄、相关检验指标、住院天数、术后并发症、肝衰竭发生率、黄疸缓解率、支架材质及通畅率等情况。结果所有患者均成功完成手术。两组在术后肝衰竭发生率、黄疸缓解率、不同材质支架在术后并发症及短期通畅率方面对比,无明显统计学意义(P>0.05)。两组患者术后总的并发症比较,差异有统计学意义(t=12.02,P<0.05),其中术后胆道感染、术后出血相比较,ERCP组分别为26.7%、11.6%,明显高于经口胰胆管镜组的10.0%、2.0%(2=5.42,3.94;P<0.05);两组患者平均住院天数比较,经口胰胆管镜组(10.78±2.17)d<ERCP组(12.91±2.96)d,差异有统计学意义(P<0.05);两组患者手术前后肝功能明显改善,相关检验指标下降明显(P<0.05);塑料支架与金属支架在术后并发症及短期通畅率方面对比,无明显差异(P>0.05),在通畅时间>6个月的情况下,金属支架通畅率明显高于塑料支架(P<0.05)。结论经ERCP与经口胰胆管镜技术置入胆管支架对于缓解高位胆管癌临床症状有效,均可提高患者生存质量。其中经口胰胆管镜技术并发症发生率低、恢复快、优势更大,但花费较高;塑料支架对预期生存时间较短的患者有益,金属支架更适用于预期生存时间较长的患者。 展开更多
关键词 胆管肿瘤 高位胆管癌 胰胆管镜 内镜下逆行胰胆管造影 胆道支架
下载PDF
经皮胆管穿刺引流介入对肝门部胆管癌患者肝功能恢复、肿瘤标志物及血清MMP-9的影响
3
作者 尹治清 陆晓 《罕少疾病杂志》 2024年第2期63-64,73,共3页
目的经皮胆管穿刺引流介入对肝门部胆管癌患者肝功能恢复、肿瘤标志物及血清基质金属蛋白酶9(MMP-9)的影响。方法选择2019年8月至2022年8月安阳市肿瘤医院收治的79例肝门部胆管癌患者,随机分为对照组(39例)和研究组(40例)。给予对照组... 目的经皮胆管穿刺引流介入对肝门部胆管癌患者肝功能恢复、肿瘤标志物及血清基质金属蛋白酶9(MMP-9)的影响。方法选择2019年8月至2022年8月安阳市肿瘤医院收治的79例肝门部胆管癌患者,随机分为对照组(39例)和研究组(40例)。给予对照组患者经内镜鼻胆管引流治疗,给予研究组患者经皮胆管穿刺引流介入治疗。将两组患者临床相关指标,治疗前后肝功能指标,血清肿瘤标志物指标、MMP-9水平,以及术后并发症总发生情况进行对比。结果两组患者手术时间、术中出血量、术后住院时间、并发症总发生率等进行对比,无差异(均P>0.05);相较于治疗前,治疗后两组患者总胆红素(TBi L)、天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)均下降,且研究组患者TBi L、AST水平均比对照组低(均P<0.05);治疗后两组患者癌胚抗原(CEA)、糖类抗原199(CA199)、糖类抗原50(CA50)、MMP-9均相较于治疗前下降,且研究组均比对照组低(均P<0.05)。结论相较于经内镜鼻胆管引流,经皮胆管穿刺引流介入治疗应用肝门胆管癌患者的治疗中,可有助于肝功能的恢复,降低血清肿瘤标志物水平及MMP-9水平,且不会增加并发症的发生。 展开更多
关键词 经皮胆管穿刺引流介入 肝门部胆管癌 肝功能 肿瘤标志物 基质金属蛋白酶9 影响
下载PDF
Risk factors and classifications of hilar cholangiocarcinoma 被引量:23
4
作者 Miguel Angel Suarez-Munoz Jose Luis Fernandez-Aguilar +5 位作者 Belinda Sanchez-Perez Jose Antonio Perez-Daga Beatriz Garcia-Albiach Ysabel Pulido-Roa Naiara Marin-Camero Julio Santoyo-Santoyo 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2013年第7期132-138,共7页
Cholangiocarcinoma is the second most common primary malignant tumor of the liver.Perihilar cholangiocarcinoma or Klatskin tumor represents more than 50% of all biliary tract cholangiocarcinomas.A wide range of risk f... Cholangiocarcinoma is the second most common primary malignant tumor of the liver.Perihilar cholangiocarcinoma or Klatskin tumor represents more than 50% of all biliary tract cholangiocarcinomas.A wide range of risk factors have been identified among patients with Perihilar cholangiocarcinoma including advanced age,male gender,primary sclerosing cholangitis,choledochal cysts,cholelithiasis,cholecystitis,parasitic infection(Opisthorchis viverrini and Clonorchis sinensis),inflammatory bowel disease,alcoholic cirrhosis,nonalcoholic cirrhosis,chronic pancreatitis and metabolic syndrome.Various classifications have been used to describe the pathologic and radiologic appearance of cholangiocarcinoma.The three systems most commonly used to evaluate Perihilar cholangiocarcinoma are the Bismuth-Corlette(BC) system,the Memorial Sloan-Kettering Cancer Center and the TNM classification.The BC classification provides preoperative assessment of local spread.The Memorial Sloan-Kettering cancer center proposes a staging system according to three factors related to local tumor extent:the location and extent of bile duct involvement,the presence or absence of portal venous invasion,and the presence or absence of hepatic lobar atrophy.The TNM classification,besides the usual descriptors,tumor,node and metastases,provides additional information concerning the possibility for the residual tumor(R) and the histological grade(G).Recently,in 2011,a new consensus classification for the Perihilar cholangiocarcinoma had been published.The consensus was organised by the European Hepato-PancreatoBiliary Association which identified the need for a new staging system for this type of tumors.The classification includes information concerning biliary or vascular(portal or arterial) involvement,lymph node status or metastases,but also other essential aspects related to the surgical risk,such as remnant hepatic volume or the possibility of underlying disease. 展开更多
关键词 hilar CHOLANGIOCARCINOMA Klatskin tumor Perihilar CHOLANGIOCARCINOMA BILE DUCT cancer
下载PDF
Palliation:Hilar cholangiocarcinoma 被引量:16
5
作者 Mahesh Kr Goenka Usha Goenka 《World Journal of Hepatology》 CAS 2014年第8期559-569,共11页
Hilar cholangiocarcinomas are common tumors of the bile duct that are often unresectable at presentation. Palliation, therefore, remains the goal in the majority of these patients. Palliative treatment is particularly... Hilar cholangiocarcinomas are common tumors of the bile duct that are often unresectable at presentation. Palliation, therefore, remains the goal in the majority of these patients. Palliative treatment is particularly indicated in the presence of cholangitis and pruritus but is often also offered for high-grade jaundice and abdominal pain. Endoscopic drainage by placing stents at endoscopic retrograde cholangio-pancreatography(ERCP) is usually the preferred modality of palliation. However, for advanced disease, percutaneous stenting has been shown to be superior to endoscopic stenting. Endosonography-guided biliary drainage is emerging as an alternative technique, particularly when ERCP is not possible or fails. Metal stents are usually preferred over plastic stents, both for ERCP and for percutaneous bili-ary drainage. There is no consensus as to whether it is necessary to place multiple stents within advanced hi-lar blocks or whether unilateral stenting would suffice. However, recent data have suggested that, contrary to previous belief, it is useful to drain more than 50% of the liver volume for favorable long-term results. In the presence of cholangitis, it is beneficial to drain all of the obstructed biliary segments. Surgical bypass plays a limited role in palliation and is offered primarily as asegment Ⅲ bypass if, during a laparotomy for resec-tion, the tumor is found to be unresectable. Photody-namic therapy and, more recently, radiofrequency abla-tion have been used as adjuvant therapies to improve the results of biliary stenting. The exact technique to be used for palliation is guided by the extent of the bili-ary involvement(Bismuth class) and the availability of local expertise. 展开更多
关键词 CHOLANGIOCARCINOMA hilar CHOLANGIOCARCINOMA Klatskin’s tumor PALLIATION BILIARY STENTING
下载PDF
Current therapy of hilar cholangiocarcinoma 被引量:6
6
作者 Stephanie Hiu Yan Lau Wan Yee Lau 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2012年第1期12-17,共6页
BACKGROUND: Hilar cholangiocarcinoma (HC) is an adeno-carcinoma of the extrahepatic biliary tree arising from the main left or right hepatic ducts or their confluence. This tumor is still considered to be difficult to... BACKGROUND: Hilar cholangiocarcinoma (HC) is an adeno-carcinoma of the extrahepatic biliary tree arising from the main left or right hepatic ducts or their confluence. This tumor is still considered to be difficult to treat or to cure. DATA SOURCES: We reviewed the medical literature on HC. Relevant and updated information on this tumor was analyzed in a concise and easy-to-read manner. The article is not intended to be a systematic review, but an extensive search was conducted on PubMed and MEDLINE using the keywords 'hilar cholangiocarcinoma' and 'Klatskin tumor' until July 2011. RESULTS: The selection and the timing of management options for patients with HC are determined by the degree of certainty of the diagnosis, the general condition of the patients, the underlying liver function and the stage of the disease. Current treatment of HC can be divided into curative and palliative treatment. For the curative treatment, local excision should only be used on small tumors which are confined to the bile duct wall and Bismuth I papillary carcinoma. Partial hepatectomy should be combined with caudate lobe resection and porta-hepatis lymph node dissection. The results of these major resections can be improved with portal vein embolization, and staging laparoscopy and laparoscopic ultrasound. The role of preoperative biliary drainage is controversial. Autotransplantation for HC gave disappointing results while the Mayo Protocol of chemoradiation for selecting patients with unresectable HC for orthotopic liver transplantation has been widely accepted. Palliative treatment included bypass surgery, endoscopic or percutaneous stenting, photodynamic therapy, intraluminal brachytherapy, and external radiation and systemic therapy. CONCLUSIONS: Adequate surgery with R0 resection should be the main goal of treatment. For patients with unresectable HC, treatment aims to improve the quality and quantity of their survival. 展开更多
关键词 hilar cholangiocarcinoma Klatskin tumor RESECTION liver transplantation palliative treatment
下载PDF
Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma:Review of the literature 被引量:7
7
作者 Fabio Frosio Federico Mocchegiani +4 位作者 Grazia Conte Enrico Dalla Bona ANDrea Vecchi Daniele Nicolini Marco Vivarelli 《World Journal of Gastrointestinal Surgery》 SCIE CAS 2019年第6期279-286,共8页
Cholangiocarcinoma(CCA)is a malignant tumor of the biliary system and includes,according to the anatomical classification,intra hepatic CCA(iCCA),hilar CCA(hCCA)and distal CCA(dCCA).Hilar CCA is the most challenging t... Cholangiocarcinoma(CCA)is a malignant tumor of the biliary system and includes,according to the anatomical classification,intra hepatic CCA(iCCA),hilar CCA(hCCA)and distal CCA(dCCA).Hilar CCA is the most challenging type in terms of diagnosis,treatment and prognosis.Surgery is the only treatment possibly providing long-term survival,but only few patients are considered resectable at the time of diagnosis.In fact,tumor’s extension to segmentary or subsegmentary biliary ducts,along with large lymph node involvement or intrahepatic metastases,precludes the surgical approach.To achieve R0 margins is mandatory for the disease-free survival and overall survival.In case of unresectable locally advanced hCCA,radiochemotherapy(RCT)as neoadjuvant treatment demonstrated to be a therapeutic option before either hepatic resection or liver transplantation.Before liver surgery,RCT is believed to enhance the R0 margins rate.For patients meeting the Mayo Clinic criteria,RCT prior to orthotopic liver transplant(OLT)has proved to produce acceptable 5-years survivals.In this review,we analyze the current role of neoadjuvant RCT before resection as well as before OLT. 展开更多
关键词 hilar CHOLANGIOCARCINOMA Klatskin tumor NEOADJUVANT treatement RADIOTHERAPY Chemotherapy HEPATIC RESECTION Liver transplantation
下载PDF
Prognostic factors and long-term outcomes of hilar cholangiocarcinoma:A single-institution experience in China 被引量:41
8
作者 Hai-Jie Hu Hui Mao +6 位作者 Anuj Shrestha Yong-Qiong Tan Wen-Jie Ma Qin Yang Jun-Ke Wang Nan-Sheng Cheng Fu-Yu Li 《World Journal of Gastroenterology》 SCIE CAS 2016年第8期2601-2610,共10页
AIM: To evaluate the prognostic factors of hilar cholangiocarcinoma in a large series of patients in a single institution.METHODS: Eight hundred and fourteen patients with a diagnosis of hilar cholangiocarcinoma that ... AIM: To evaluate the prognostic factors of hilar cholangiocarcinoma in a large series of patients in a single institution.METHODS: Eight hundred and fourteen patients with a diagnosis of hilar cholangiocarcinoma that were evaluated and treated between 1990 and 2014, of which 381 patients underwent curative surgery, were included in this study. Potential factors associated with overall survival(OS) and disease-free survival(DFS) were evaluated by univariate and multivariate analyses.RESULTS: Curative surgery provided the best long-term survival with a median OS of 26.3 mo. The median DFS was 18.1 mo. Multivariate analysis showed that patients with tumor size > 3 cm [hazard ratio(HR) = 1.482, 95%CI: 1.127-1.949; P = 0.005], positive nodal disease(HR = 1.701, 95%CI: 1.346-2.149; P < 0.001), poor differentiation(HR = 2.535, 95%CI: 1.839-3.493; P < 0.001), vascular invasion(HR = 1.542, 95%CI: 1.082-2.197; P = 0.017), and positive margins(HR = 1.798, 95%CI: 1.314-2.461; P < 0.001) had poor OS outcome. The independent factors for DFS were positive nodal disease(HR = 3.383, 95%CI: 2.633-4.348; P < 0.001), poor differentiation(HR = 2.774, 95%CI: 2.012-3.823; P < 0.001), vascular invasion(HR = 2.136, 95%CI: 1.658-3.236; P < 0.001), and positive margins(HR = 1.835, 95%CI: 1.256-2.679; P < 0.001). Multiple logistic regression analysis showed that caudate lobectomy [odds ratio(OR) = 9.771, 95%CI: 4.672-20.433; P < 0.001], tumor diameter(OR = 3.772, 95%CI: 1.914-7.434; P < 0.001), surgical procedures(OR = 10.236, 95%CI: 4.738-22.116; P < 0.001), American Joint Committee On Cancer T stage(OR = 2.010, 95%CI: 1.043-3.870; P = 0.037), and vascular invasion(OR = 2.278, 95%CI: 0.997-5.207; P = 0.051) were independently associated with tumorfree margin, and surgical procedures could indirectly affect survival outcome by influencing the tumor resection margin. CONCLUSION: Tumor margin, tumor differentiation, vascular invasion, and lymph node status were independent factors for OS and DFS. Surgical procedures can indirectly affect survival outcome by influencing the tumor resection margin. 展开更多
关键词 hilar CHOLANGIOCARCINOMA Prognosis SURGICAL OUTCOME Survival tumor-free MARGIN
下载PDF
Pathological aspects of so called "hilar cholangiocarcinoma" 被引量:9
9
作者 Víctor M Castellano-Megías Carolina Ibarrola-de Andrés Francisco Colina-Ruizdelgado 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2013年第7期159-170,共12页
Cholangiocarcinoma(CC) arising from the large intrahepatic bile ducts and extrahepatic hilar bile ducts share clinicopathological features and have been called hilar and perihilar CC as a group.However,"hilar and... Cholangiocarcinoma(CC) arising from the large intrahepatic bile ducts and extrahepatic hilar bile ducts share clinicopathological features and have been called hilar and perihilar CC as a group.However,"hilar and perihilar CC" are also used to refer exclusively to the intrahepatic hilar type CC or,more commonly,the extrahepatic hilar CC.Grossly,a major distinction can be made between papillary and non-papillary tumors.Histologically,most hilar CCs are well to moderately differentiated conventional type(biliary) carcinomas.Immunohistochemically,CK7,CK20,CEA and MUC1 are normally expressed,being MUC2 positive in less than 50% of cases.Two main premalignant lesions are known:biliary intraepithelial neoplasia(BilIN) and intraductal papillary neoplasm of the biliary tract(IPNB).IPNB includes the lesions previously named biliary papillomatosis and papillary carcinoma.A series of 29 resected hilar CC from our archives is reviewed.Most(82.8%) were conventional type adenocarcinomas,mostly well to moderately differentiated,although with a broad morphological spectrum;three cases exhibited a poorly differentiated cell component resembling signet ring cells.IPNB was observed in 5(17.2%),four of them with an associated invasive carcinoma.A clear cell type carcinoma,an adenosquamous carcinoma and two gastric foveolar type carcinomas were observed. 展开更多
关键词 CHOLANGIOCARCINOMA BILE DUCT CARCINOMA hilar CHOLANGIOCARCINOMA Perihilar CHOLANGIOCARCINOMA Klatskin tumor EXTRAHEPATIC BILE DUCT CARCINOMA Hepatic hilum
下载PDF
不可逆电穿孔治疗肝门区域肿瘤的优势
10
作者 王小雯 赵建军 《肝癌电子杂志》 2023年第1期31-34,共4页
肝脏肿瘤的局部治疗方式有手术切除、介入术、热消融术和冷冻消融术等,这些治疗手段在临床中能治疗大多数肝脏肿瘤。然而,由于肝门区域肿瘤的位置毗邻血管、神经和胆道等重要结构,肝门区域肿瘤的切除率或者毁损率、肿瘤周围管道结构的... 肝脏肿瘤的局部治疗方式有手术切除、介入术、热消融术和冷冻消融术等,这些治疗手段在临床中能治疗大多数肝脏肿瘤。然而,由于肝门区域肿瘤的位置毗邻血管、神经和胆道等重要结构,肝门区域肿瘤的切除率或者毁损率、肿瘤周围管道结构的保护、治疗误损伤、肝硬化患者残肝的保护、降低并发症等各方面要达到良好的平衡,传统局部治疗方式处理肝门区域肿瘤存在一定的局限性。不可逆电穿孔(irreversible electroporation,IRE)消融术由于其引导细胞凋亡,保护血管、胆管等重要结构不受热损伤的特点,因此在治疗肝门区域特殊部位肿瘤中具有更加明显的优势。本文主要介绍与传统热消融术相比,IRE消融术治疗肝门区域特殊部位肿瘤的优势。 展开更多
关键词 不可逆电穿孔 肝门区域肿瘤 有效性 安全性
下载PDF
Revolution CT多模式重建对肝门部胆管癌术前分期及手术方式评估的研究
11
作者 李香霞 徐彦东 《局解手术学杂志》 2023年第8期712-715,共4页
目的探究Revolution CT多模式重建对肝门部胆管癌(HCCA)术前分期及手术方式的评估价值。方法选取鄂尔多斯市中心医院89例HCCA患者,术前均行Revolution CT多模式重建,以手术病理诊断结果为金标准,分析Revolution CT多模式重建诊断HCCA肿... 目的探究Revolution CT多模式重建对肝门部胆管癌(HCCA)术前分期及手术方式的评估价值。方法选取鄂尔多斯市中心医院89例HCCA患者,术前均行Revolution CT多模式重建,以手术病理诊断结果为金标准,分析Revolution CT多模式重建诊断HCCA肿瘤类型、肝叶萎缩、肝动脉侵犯、门静脉侵犯、淋巴结转移、Bismuth-Corlette分型、临床分期及手术可切除性的价值。结果Revolution CT多模式重建诊断的HCCA肿瘤类型与手术病理诊断结果一致,诊断准确率为100%。Revolution CT多模式重建诊断HCCA肝叶萎缩、肝动脉侵犯、门静脉侵犯、淋巴结转移结果与手术病理诊断结果比较,差异无统计学意义(P>0.05)。Revolution CT多模式重建诊断HCCA Bismuth-Corlette分型与手术病理诊断的Kappa值为0.886(95%CI:0.781~0.992),诊断符合率为91.01%(P<0.05)。Revolution CT多模式重建诊断HCCA临床分期与手术病理诊断的Kappa值为0.891(95%CI:0.766~1.016),诊断符合率为92.13%(P<0.05)。Revolution CT多模式重建诊断HCCA手术可切除性与手术病理诊断的Kappa值为0.887(95%CI:0.681~1.094),诊断符合率为94.38%(P<0.05)。结论Revolution CT多模式重建能准确判断术前HCCA肿瘤类型、Bismuth-Corlette分型和临床分期,可为临床制定个性化手术方案提供可靠依据。 展开更多
关键词 肝门部胆管癌 CT多模式重建 临床分期 肿瘤分型
下载PDF
CT导向下^(125)I粒子植入治疗肝门区肝癌 被引量:71
12
作者 刘健 张福君 +3 位作者 吴沛宏 顾仰葵 陈林 张亮 《介入放射学杂志》 CSCD 2005年第6期606-609,共4页
目的评价CT导向下125I粒子植入治疗肝门区肝癌及淋巴结的临床价值。方法本组病例32例,其中肝门区肝细胞癌(HCC)8例,肝门区胆管癌(HC)12例,肝转移瘤6例,肝门区淋巴结转移6例。14例侵犯肝门胆管致肝内胆管扩张,22例合并肝硬化。全部病例... 目的评价CT导向下125I粒子植入治疗肝门区肝癌及淋巴结的临床价值。方法本组病例32例,其中肝门区肝细胞癌(HCC)8例,肝门区胆管癌(HC)12例,肝转移瘤6例,肝门区淋巴结转移6例。14例侵犯肝门胆管致肝内胆管扩张,22例合并肝硬化。全部病例经CT、MRI检查或病理穿刺活检证实。病灶平均直径为4.2 cm。采用TPS计算布源,在CT导向下将125I粒子植入瘤灶内,采用0.6~0.9 mCi活度的125I粒子相隔1.0~1.5 cm平面播植。结果2例死于远处转移,3例死于肝功能衰竭,全组中位生存时间10个月。2个月后CT复查,完全缓解(CR)2例;部分缓解(PR)20例;无变化(NC)5例;进展(PD)5例。总有效率(CR+PR)68.8%。2个月随访过程中发现7颗粒子在肝脏内游走,3颗粒子迁徙至肺内;1例出现气胸,肺压缩在30%以下,白细胞轻度下降1例。未见大出血、胆汁瘘、肠瘘、肠出血等严重并发症。结论CT导向下放射性粒子植入治疗肝门区肿瘤及淋巴结创伤小,并发症发生率低,生活质量改善明显,近期效果好,是治疗中晚期肝门区肿瘤及淋巴结的简单、安全、有效的方法。 展开更多
关键词 碘放射性核素 放射学 介入性 近距离放射疗法 肝门区肿瘤及淋巴结 评价研究
下载PDF
肾门旁肿瘤行经腹膜后与经腹腹腔镜下肾部分切除术的对比分析 被引量:10
13
作者 门昌平 赵俊杰 +6 位作者 杨典东 林春华 王科 王辉 崔元善 吴吉涛 高振利 《中国医学前沿杂志(电子版)》 2017年第1期107-111,共5页
目的对比分析经腹膜后与经腹2种腹腔镜入路下肾门旁肿瘤的肾部分切除术的术后情况。方法回顾性分析自2013年1月至2016年12月于本院行腹腔镜下肾部分切除术的38例肾门旁肿瘤患者的临床资料,根据腹腔镜入路方式不同将患者分为经腹膜后入路... 目的对比分析经腹膜后与经腹2种腹腔镜入路下肾门旁肿瘤的肾部分切除术的术后情况。方法回顾性分析自2013年1月至2016年12月于本院行腹腔镜下肾部分切除术的38例肾门旁肿瘤患者的临床资料,根据腹腔镜入路方式不同将患者分为经腹膜后入路组(23例)和经腹入路组(15例),对两组患者手术时间、术中出血量、热缺血时间、术后出血、术后尿漏、手术切缘阳性、术后通气时间、平均住院天数等因素进行对比分析。结果两组患者的手术时间、术中出血量、平均热缺血时间、术后出血、术后尿漏、手术切缘阳性比较均无显著差异(P<0.05);但经腹膜后入路组患者术后通气时间和平均住院时间均短于经腹入路组(P<0.05)。结论肾门旁肿瘤腹腔镜肾部分切除经腹膜后和经腹腔路径均是可行的,但与经腹入路相比,经腹膜后入路患者术后肠道恢复更快,更有利于快速康复。 展开更多
关键词 腹腔镜 肾肿瘤 肾门旁肿瘤 肾部分切除术
下载PDF
腹腔镜肾部分切除术治疗T1期肾门肿瘤的临床研究 被引量:6
14
作者 宋健 王磊 +7 位作者 吕文成 王文营 张道新 李军 杨培谦 郝钢跃 郭宇文 田野 《临床和实验医学杂志》 2014年第19期1618-1621,共4页
目的:探讨腹腔镜肾部分切除术治疗T1期肾门肿瘤的经验。方法回顾2004年6月至2013年6月腹腔镜肾部分切除术治疗12例T1期肾门肿瘤,肾门肿瘤定义为距离肾门血管或肾脏集合系统小于5 mm的肾肿瘤。其中左侧7例、右侧5例,平均年龄58岁(46... 目的:探讨腹腔镜肾部分切除术治疗T1期肾门肿瘤的经验。方法回顾2004年6月至2013年6月腹腔镜肾部分切除术治疗12例T1期肾门肿瘤,肾门肿瘤定义为距离肾门血管或肾脏集合系统小于5 mm的肾肿瘤。其中左侧7例、右侧5例,平均年龄58岁(46~72岁),肿瘤直径平均3.6 cm(2.4~7 cm),观察临床疗效。结果全部患者顺利完成手术。平均手术时间80 min(50~140 min),平均热缺血时间28 min(18~45 min),术中平均出血量127 ml (50~340 ml)。术后迟发性出血2例,漏尿1例,术后住院时间平均7.2天(5~14天)。术后病理透明细胞癌8例,嫌色细胞癌2例,血管平滑肌脂肪瘤2例。随访5~48月,2例复发。全部患者术后肾功能正常。结论腹腔镜肾部分切除术治疗T1期肾门肿瘤可行,熟练的腹腔镜技术和术者的临床经验对于成功开展该治疗具有重要作用。 展开更多
关键词 肾门肿瘤 腹腔镜 肾部分切除术
下载PDF
后腹腔镜肾部分切除术治疗T1a期肾门旁肿瘤 被引量:11
15
作者 王欢 种铁 +5 位作者 李波涌 李斌 李美霞 李雯 陆弦 郑文博 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2019年第3期451-454,485,共5页
目的分析后腹腔镜肾部分切除术(laparoscopic partial nephrectomy, LPN)治疗T1a期肾门旁肿瘤的安全性和有效性。方法回顾性分析2008年9月至2018年5月间LPN治疗11例肾门旁肿瘤患者的资料。收集患者的一般情况、临床资料、影像学资料、... 目的分析后腹腔镜肾部分切除术(laparoscopic partial nephrectomy, LPN)治疗T1a期肾门旁肿瘤的安全性和有效性。方法回顾性分析2008年9月至2018年5月间LPN治疗11例肾门旁肿瘤患者的资料。收集患者的一般情况、临床资料、影像学资料、手术结果、病理结果和随访结果。结果 11例患者的中位年龄46(26~75)岁,中位肿瘤直径3.0(2.3~4.0)cm,中位R.E.N.A.L评分5(4~7)分。临床分期均为T1aN0M0。全部患者成功完成手术,中位热缺血时间35(23~56)min,中位手术时间180(150~240)min,中位估计失血量为100(50~300)mL。3例患者术中行集合系统修补术。术后1例输血,2例短暂性血尿,1例低热,1例出现漏尿,保守治疗后好转;中位术后住院时间7(5~13)d;术后病理诊断:透明细胞癌8例,嫌色肾细胞癌1例,乳头状肾细胞癌1例,血管平滑肌脂肪瘤1例。10例肾细胞癌(renal cell carcinoma, RCC)术后病理分期均为T1aN0M0。4例患者术中做切缘活检,结果均阴性。术后中位随访时间33(1~80)个月,均未出现局部复发或转移。结论对于T1a期的肾门旁肿瘤,LPN是安全可行的手术方式,熟练的腹腔镜技术和术者的临床经验是手术成功的重要因素。 展开更多
关键词 肾门旁肿瘤 腹腔镜 肾部分切除术
下载PDF
机器人辅助腹腔镜肾部分切除术处理肾门偏上极骑跨肾血管及肾门前后唇部位肾门肿瘤 被引量:2
16
作者 管维 张宗彪 +3 位作者 杨俊 卢宇超 刘征 王少刚 《第二军医大学学报》 CAS CSCD 北大核心 2020年第7期714-720,共7页
目的评估机器人辅助腹腔镜肾部分切除术(RAPN)治疗特殊肾门部位(肾门偏上极骑跨肾血管及肾门前后唇,HUS)肿瘤的疗效和安全性。方法回顾性分析2016年2月至2018年12月于我院接受RAPN治疗的患者临床基本资料,筛选出典型HUS部位肾门肿瘤13例... 目的评估机器人辅助腹腔镜肾部分切除术(RAPN)治疗特殊肾门部位(肾门偏上极骑跨肾血管及肾门前后唇,HUS)肿瘤的疗效和安全性。方法回顾性分析2016年2月至2018年12月于我院接受RAPN治疗的患者临床基本资料,筛选出典型HUS部位肾门肿瘤13例(HUS组),并筛选R.E.N.A.L.评分与之相当的13例非HUS部位肾门肿瘤(非HUS组)作为对照。分析并比较两组患者基本资料、围手术期结果、并发症、肾功能变化和肿瘤复发转移情况。结果两组患者肿瘤最大直径、R.E.N.A.L.评分具有较好的可比性,但HUS组中有3例手术中转开放肾部分切除术。与非HUS组相比,HUS组的手术时间[(132.92±22.33)min vs(110.85±20.97)min]和肾脏热缺血时间[(28.08±6.29)min vs(22.15±5.87)min]均较长,差异均有统计学意义(P均<0.05)。两组患者的术中出血量、输血率、术后住院时间、术后短期肾功能变化、切缘阳性率、并发症发生率、“三连胜”(trifecta)达标率差异均无统计学意义(P均>0.05)。随访期间两组患者均无复发转移、无死亡。结论HUS部位肾门肿瘤行RAPN需要更长的手术时间和肾脏阻断时间,并且术中更改手术方式的概率也较大,需要根据肿瘤特征和术者经验合理选择手术方式。 展开更多
关键词 肾肿瘤 肾门肿瘤 机器人手术 腹腔镜技术 肾部分切除术
下载PDF
肝门部肿瘤32例影像学分析及术前评估 被引量:3
17
作者 孙丽娟 袁曙光 +1 位作者 彭艳霞 王家平 《医学影像学杂志》 2008年第2期139-141,共3页
目的:探讨超声、螺旋CT、MRI对肝门部肿瘤的诊断价值及MRI对病变术前评估的意义。方法:回顾性分析32例肝门部肿瘤(其中肝细胞癌(HCC)6例,胆管癌(HC)16例,转移性病变8例,血管瘤2例),均具超声、MRI影像资料,16例具有螺旋CT资料,并与手术.... 目的:探讨超声、螺旋CT、MRI对肝门部肿瘤的诊断价值及MRI对病变术前评估的意义。方法:回顾性分析32例肝门部肿瘤(其中肝细胞癌(HCC)6例,胆管癌(HC)16例,转移性病变8例,血管瘤2例),均具超声、MRI影像资料,16例具有螺旋CT资料,并与手术.病理结果比较。结果:(1)超声、螺旋CT、MRI对肝门部肿瘤的检出率分别为63.3%;81.3%;100%;(2)MRI对其定性准确率为75%;MRI三种组合扫描方式:((1)平扫+MRCP;((2)"(1)"+动态增强扫描;(3)"(2)"+三维动态增强磁共振血管成像(3DDCE-MRA))其对病变能否切除评估准确率分别为43.8%;59.4%;78.1%。结论:超声对肝门部肿瘤的准确诊断显示欠满意,但对其伴随征象具有一定价值;CT、MRI是病变有效的诊断方法,MRI在显示肿块范围、胆管及门静脉受侵、淋巴结肿大方面优于CT;MRI多种扫描方式相结合对病变术前评估具有重要意义。 展开更多
关键词 肝门部肿瘤 影像诊断 术前评估
下载PDF
肝门胆管癌的治疗进展 被引量:12
18
作者 詹茜 沈柏用 《世界华人消化杂志》 CAS 北大核心 2009年第32期3313-3317,共5页
肝门部胆管癌因其发生部位特殊、呈浸润性生长及与肝门部血管关系密切等特点给手术切除造成极大的困难.长期以来,肝门部胆管癌被认为是无法手术根治性切除的癌肿.近20年来,随着影像学和手术技术的进步,使肝门部胆管癌的诊断和治疗取得... 肝门部胆管癌因其发生部位特殊、呈浸润性生长及与肝门部血管关系密切等特点给手术切除造成极大的困难.长期以来,肝门部胆管癌被认为是无法手术根治性切除的癌肿.近20年来,随着影像学和手术技术的进步,使肝门部胆管癌的诊断和治疗取得重大进步,手术切除率逐步提高,生存率得到明显改善.但是对于是否应行扩大根治术、血管切除重建,以及放化疗等的疗效问题,依然是肝胆外科及肿瘤科医生所面临的严峻挑战.本文就肝门部胆管癌的治疗进展作一综述. 展开更多
关键词 肝门胆管癌 肿瘤 治疗
下载PDF
肝门部胆管癌病理特征与术后随访结果分析(附113例报告) 被引量:12
19
作者 孟翔飞 周宁新 +3 位作者 肖梅 李铸 丁振昊 黄志强 《消化外科》 CSCD 2006年第1期49-51,共3页
目的评估肝门部胆管癌的病理特征对术后生存的影响并为临床治疗提供依据。方法回顾性分析1997年1月至2002年12月我院肝胆外科113例手术切除的肝门部胆管癌病理资料,并结合随访结果进行统计分析。结果高分化腺癌18例、中分化腺癌38例,低... 目的评估肝门部胆管癌的病理特征对术后生存的影响并为临床治疗提供依据。方法回顾性分析1997年1月至2002年12月我院肝胆外科113例手术切除的肝门部胆管癌病理资料,并结合随访结果进行统计分析。结果高分化腺癌18例、中分化腺癌38例,低分化腺癌38例,黏液腺癌4例,其他类型15例。高、中、低分化腺癌术后5年生存率分别为57.0%,10.9%,18.8%,高分化与中低分化组间比较差异有显著性(P<0.05)。浸润能力高分化腺癌最弱、中低分化腺癌较强,黏液腺癌最强。分化程度,淋巴结转移、神经转移对术后生存时间均有显著影响(P<0.05)。结论肝门部胆管癌的分化程度、淋巴转移是影响预后的重要因素,神经转移对预后的影响仍需深入研究。 展开更多
关键词 胆管肿瘤 肝门部胆管癌 预后
下载PDF
人工智能在鉴别肝门部胆管癌细胞及周围神经侵袭中的应用 被引量:2
20
作者 顾小强 俞文隆 +4 位作者 陈颖 魏培莲 董伟 钱建新 于观贞 《第二军医大学学报》 CAS CSCD 北大核心 2021年第7期724-730,共7页
目的建立一种用于辅助诊断肝门部胆管癌(HC)的人工智能(AI)算法模型,评价其识别肿瘤细胞及周围神经侵犯(PNI)的能力。方法采用AI算法对825张HC和175张非癌变组织图像(600张为训练集,300张为测试集,100张为比较数据集)进行深度学习,将不... 目的建立一种用于辅助诊断肝门部胆管癌(HC)的人工智能(AI)算法模型,评价其识别肿瘤细胞及周围神经侵犯(PNI)的能力。方法采用AI算法对825张HC和175张非癌变组织图像(600张为训练集,300张为测试集,100张为比较数据集)进行深度学习,将不同参数的GoogLeNet和DenseNet相结合的神经网络用于HC细胞和PNI的特征提取和深度学习。比较该AI算法模型与3名病理科医师(副主任医师、主治医师、住院医师各1名)在判断肿瘤有无及肿瘤细胞百分比的差异。结果基于深度学习的AI算法可以准确识别HC组织标本图像中的肿瘤细胞及PNI。AI算法诊断肿瘤的能力可与经验丰富的病理科副主任医师媲美,且在评估肿瘤细胞百分比方面更胜一筹。结论AI算法模型在识别HC肿瘤细胞及PNI方面具有辅助作用。 展开更多
关键词 人工智能 肝门部胆管癌 肿瘤间质比 神经侵犯
下载PDF
上一页 1 2 5 下一页 到第
使用帮助 返回顶部